KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) Accumulated Depreciation & Amortization (2016 - 2025)

Sarepta Therapeutics (SRPT) has 13 years of Accumulated Depreciation & Amortization data on record, last reported at $37.7 million in Q4 2024.

  • For Q4 2024, Accumulated Depreciation & Amortization fell 15.03% year-over-year to $37.7 million; the TTM value through Dec 2024 reached $37.7 million, down 15.03%, while the annual FY2024 figure was $37.7 million, 15.03% down from the prior year.
  • Accumulated Depreciation & Amortization reached $37.7 million in Q4 2024 per SRPT's latest filing, down from $44.4 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $112.6 million in Q4 2021 and bottomed at $37.7 million in Q4 2024.
  • Average Accumulated Depreciation & Amortization over 5 years is $62.5 million, with a median of $44.4 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: soared 49.09% in 2020, then tumbled 62.83% in 2022.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $76.0 million in 2020, then soared by 48.15% to $112.6 million in 2021, then crashed by 62.83% to $41.9 million in 2022, then grew by 6.05% to $44.4 million in 2023, then decreased by 15.03% to $37.7 million in 2024.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $37.7 million in Q4 2024, $44.4 million in Q4 2023, and $41.9 million in Q4 2022.